Quick Answer
BioNTech SE reported R&D Expense of $2.10 billion for fiscal year 2025.
BioNTech SE R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.10B | -6.6% |
| 2024 | $2.25B | +26.4% |
| 2023 | $1.78B | +16.0% |
| 2022 | $1.54B | +61.9% |
| 2021 | $949.20M | +47.2% |
| 2020 | $645.00M | +184.8% |
| 2019 | $226.50M | +58.3% |
| 2018 | $143.04M | +67.3% |
| 2017 | $85.50M | — |
- BioNTech SE showed a decrease of -6.6% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, BioNTech SE’s r&d expense has grown by 2362.0% (from $85.50 million to $2.10 billion).
- The most recent figure is from BioNTech SE’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: